MEI Pharma Inc. (NASDAQ:MEIP) is moving higher on Thursday. The stock bounced nicely off at the start of the day. This may be a good sign.
As at 10:19, MEIP is trading at $2.77, up $0.06 gaining 2.54% so far on the day. Volume is 109k shares. MEIP opened at $2.75 and has traded in a range between $2.72 and $2.79.
MEI Pharma And Kyowa Announces Clinical Data
- MEI Pharma and Kyowa Kirin make an announcement on new Clinical data of Zandelisib at the American Society of Clinical Oncology Annual Meeting 2021.
- Zandelisib demonstrated that patients with relapsed of refractory follicular lymphoma had an 82% response rate, had an progression of disease within 24 months of first line of chemoimmunotherapy have an overall response rate of 93% in non-POD24.
- Zandelisib and zanubrutinibcombination therapy demonstrated that patients with indolent B-cell malignancies showed a 100% response rate. The combination therapy added an optimized dosing regimen with no additive toxicity to each of the agents alone.
“We are encouraged by the zandelisib data being shared at this year’s ASCO Annual Meeting, specifically the data that showed zandelisib activity across differing patient groups, including POD24 – a group that typically has a poor prognosis and would generally be expected to meet the inclusion criteria of our Phase 3 COASTAL study. Additionally, the data reporting on the combination of zandelisib and zanubrutinib, demonstrated the potential to induce robust and durable responses against various B-cell malignancies with a combination that is generally well-tolerated,” said Richard Ghalie, M.D., chief medical officer at MEI Pharma.